Early High Efficacy Treatment in Multiple Sclerosis Is the Best Predictor of Future Disease Activity Over 1 and 2 Years in a Norwegian Population-Based Registry

Background: Moderate and high efficacy disease modifying therapies (DMTs) have a profound effect on disease activity. The current treatment guidelines only recommend high efficacy DMTs for patients with highly active MS. The objective was to examine the impact of initial treatment choice in achievin...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Front Neurol
Hlavní autoři: Simonsen, Cecilia Smith, Flemmen, Heidi Øyen, Broch, Line, Brunborg, Cathrine, Berg-Hansen, Pål, Moen, Stine Marit, Celius, Elisabeth Gulowsen
Médium: Artigo
Jazyk:Inglês
Vydáno: Frontiers Media S.A. 2021
Témata:
Neurology
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8248666/
https://ncbi.nlm.nih.gov/pubmed/34220694
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fneur.2021.693017
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky